CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis.
Kaneshita S, Kida T, Yoshioka M, Nishioka K, Raje M, Sakashita A, Hirano A, Sagawa T, Kasahara A, Inoue T, Fujioka K, Nagahara H, Wada M, Kohno M, Strovel JW, Fletcher S, Ashihara E, Kawahito Y.
Kaneshita S, et al. Among authors: nagahara h.
Pulm Pharmacol Ther. 2021 Oct;70:102057. doi: 10.1016/j.pupt.2021.102057. Epub 2021 Aug 20.
Pulm Pharmacol Ther. 2021.
PMID: 34425215